Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
Abramson Cancer Center at Penn Medicine
Summary
The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.
Description
Endoscopic Ultrasound (EUS) has emerged as a critical component in the imaging, staging, and diagnosis of pancreatic cancer. Not only can EUS delineate a mass utilizing sonography through the wall of the stomach or duodenum, but it also can obtain diagnostic fine needle aspiration of suspicious lesions. Especially in patients with incomplete visualization of a mass on cross-sectional imaging, EUS can provide valuable anatomic information prior to surgical exploration. While several studies have demonstrated that EUS has high sensitivity and specificity in diagnosing pancreatic masses, head-to-…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria * Age \>= 18 * Documented germline pathogenic or likely pathogenic BRCA1, BRCA2, ATM, or PALB2 mutation * If no history of PDAC in a first or second degree relative, age \>= 50 * If there is a history of PDAC in a first or second degree relative, minimum age of eligibility is 10 years younger than the age of onset of the youngest relative with pancreatic cancer Exclusion Criteria • Pregnancy
Interventions
- OtherCollection of data from endoscopic ultrasound or MRI/MRCP of the abdomen
Participants in this study should be undergoing pancreatic cancer screening with endoscopic ultrasound or MRI as part of their standard care. These should typically be done at least every 12 months, and the imaging tests will be ordered as routine clinical tests and will be billed to the participant's insurance. This study does not cover the costs of these screening tests, however the study will track the results of these screening tests.
- OtherBlood sample collection for research
Up to 40mL of blood may be collected for analysis at each screening examination.
Location
- Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania